News | Breast Imaging | December 16, 2024

With ASPIRE Cristalle AWS, organizations within the DoD network will be able to securely acquire and access patients’ mammography images. 


 Dec. 16, 2024 — FUJIFILM Healthcare Americas Corporation has announced that its ASPIRE Cristalle Acquisition Workflow System (AWS), the workstation that is used in conjunction with the company’s 3D mammography system, has been granted a Risk Management Framework (RMF) and Authority to Operate (ATO) on U.S. Department of Defense (DoD) networks. 

The three-year ATO was awarded to Fujifilm for its ASPIRE Cristalle AWS version 9.x. The ASPIRE Cristalle AWS controls the exposure unit to acquire and process mammographic images. With this user-friendly, secure workstation, the operator can acquire and view the patient’s image(s) in as few as five seconds. With ASPIRE Cristalle AWS, organizations within the DoD network will be able to securely acquire and access patients’ mammography images.  

The DoD’s RMF provides a process that integrates security and risk management activities into the system development life cycle. The risk-based approach to security control selection and specification considers effectiveness, efficiency, and constraints due to applicable laws, directives, executive orders, policies, standards, and regulations. 

“This prestigious designation from the U.S. Government attests to Fujifilm’s commitment to delivering advanced solutions in women’s health that meet the most rigorous security standards,” says Henry Izawa, president and chief executive officer, FUJIFILM Healthcare America Corporation. “We are honored to have earned the ATO for our ASPIRE Cristalle AWS—technology which will optimize the end user’s workflow and will ultimately benefit physicians and patients throughout the Military Health System.” 

Click here to learn more about Fujifilm’s ASPIRE Cristalle AWS.  


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Ultrasound Women's Health

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results ...

Time September 30, 2026
arrow
News | Women's Health

Sept. 1, 2026 — On Sept. 24, 2026 at 1 p.m. EDT, Siemens Healthineers will present a webinar on "Advancing Women's ...

Time September 03, 2026
arrow
Subscribe Now